These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38404585)

  • 41. Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study.
    Liao Y; Wang B; Huang ZL; Shi M; Yu XJ; Zheng L; Li S; Li L
    PLoS One; 2013; 8(4):e60444. PubMed ID: 23565248
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical Significance of Peripheral Blood Lymphocyte Subtypes and Cytokines in Patients with Hepatocellular Carcinoma Treated with TACE.
    Wang H; Zhang G; Fan W; Wu Y; Zhang J; Xue M; Zhao Y; Yao W; Li J
    Cancer Manag Res; 2022; 14():451-464. PubMed ID: 35153515
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
    Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
    Front Immunol; 2018; 9():727. PubMed ID: 29910795
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PD-1 expression in hepatocellular carcinoma predicts liver-directed therapy response and bridge-to-transplant survival.
    Núñez KG; Sandow T; Fort D; Hibino M; Wright P; Cohen AJ; Thevenot PT
    Cancer Immunol Immunother; 2022 Jun; 71(6):1453-1465. PubMed ID: 34689234
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peripheral lymphocyte populations in ovarian cancer patients and correlations with clinicopathological features.
    Ye S; Chen W; Zheng Y; Wu Y; Xiang L; Li T; Ping B; Zhang X; Yang H
    J Ovarian Res; 2022 Apr; 15(1):43. PubMed ID: 35410290
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor.
    Zhang L; Sun T; Sun B; Zhang K; Zheng Y; Li N; Chen L; Zheng C; Liang B; Shi H
    BMC Cancer; 2024 Feb; 24(1):223. PubMed ID: 38365678
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic significance of peripheral CD8+CD28+ and CD8+CD28- T cells in advanced non-small cell lung cancer patients treated with chemo(radio)therapy.
    Liu C; Jing W; An N; Li A; Yan W; Zhu H; Yu J
    J Transl Med; 2019 Oct; 17(1):344. PubMed ID: 31623615
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical prognostic value of CD4+CD25+FOXP3+regulatory T cells in peripheral blood of Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma patients.
    Li F; Guo Z; Lizée G; Yu H; Wang H; Si T
    Clin Chem Lab Med; 2014 Sep; 52(9):1357-65. PubMed ID: 24646790
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD38 marks the exhausted CD8
    Reolo MJY; Otsuka M; Seow JJW; Lee J; Lee YH; Nguyen PHD; Lim CJ; Wasser M; Chua C; Lim TKH; Leow WQ; Chung A; Goh BKP; Chow PKH; DasGupta R; Yeong JPS; Chew V
    Front Immunol; 2023; 14():1182016. PubMed ID: 37377962
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma.
    Zhang Z; Jiao T; Li J; Hu B; Zhang W; Wang Z; Wan T; Wang Y; Lu S
    World J Surg Oncol; 2023 Feb; 21(1):53. PubMed ID: 36803872
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of Postoperative Adjuvant Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients with Mesenchymal Circulating Tumor Cell.
    Zhang J; Peng H; Wang B; Luo L; Cheng Y; He G; Tang Y; Pan M
    J Gastrointest Surg; 2021 Jul; 25(7):1770-1778. PubMed ID: 32748340
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE.
    Zhang J; Li H; Gao D; Zhang B; Zheng M; Lun M; Wei M; Duan R; Guo M; Hua J; Liu Q; Bai J; Liu H; Zheng J; Yao H
    Cancer Biol Ther; 2018 Jun; 19(6):475-483. PubMed ID: 29400599
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.
    Schobert IT; Savic LJ; Chapiro J; Bousabarah K; Chen E; Laage-Gaupp F; Tefera J; Nezami N; Lin M; Pollak J; Schlachter T
    Eur Radiol; 2020 Oct; 30(10):5663-5673. PubMed ID: 32424595
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy.
    Craciun L; de Wind R; Demetter P; Lucidi V; Bohlok A; Michiels S; Bouazza F; Vouche M; Tancredi I; Verset G; Garaud S; Naveaux C; Galdon MG; Gallo KW; Hendlisz A; Derijckere ID; Flamen P; Larsimont D; Donckier V
    BMC Cancer; 2020 Feb; 20(1):135. PubMed ID: 32075608
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of endogenous glucocorticoid on response to immune checkpoint blockade in patients with advanced cancer.
    Cui Y; Han X; Liu H; Xie Q; Guan Y; Yin B; Xiao J; Feng D; Wang X; Li J; Chen J; Liu X; Li X; Nie W; Ma L; Liu H; Liang J; Li Y; Wang B; Wang J
    Front Immunol; 2023; 14():1081790. PubMed ID: 37114049
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma.
    Lin ZH; Jiang JR; Ma XK; Chen J; Li HP; Li X; Wu XY; Huang MS; Lin Q
    Clin Exp Med; 2021 Feb; 21(1):109-120. PubMed ID: 33037574
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations.
    Kotwal A; Gustafson MP; Bornschlegl S; Kottschade L; Delivanis DA; Dietz AB; Gandhi M; Ryder M
    Thyroid; 2020 Oct; 30(10):1440-1450. PubMed ID: 32323619
    [No Abstract]   [Full Text] [Related]  

  • 60. Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma.
    Chang H; Jung W; Kim A; Kim HK; Kim WB; Kim JH; Kim BH
    APMIS; 2017 Aug; 125(8):690-698. PubMed ID: 28493410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.